L
Luis V. Syro
Researcher at University of Toronto
Publications - 84
Citations - 2732
Luis V. Syro is an academic researcher from University of Toronto. The author has contributed to research in topics: Pituitary tumors & Pituitary adenoma. The author has an hindex of 25, co-authored 82 publications receiving 2288 citations. Previous affiliations of Luis V. Syro include St. Michael's GAA, Sligo.
Papers
More filters
Journal Article
Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.
Farshad Nassiri,Michael D. Cusimano,Bernd W. Scheithauer,Fabio Rotondo,Alessandra Fazio,George M. Yousef,Luis V. Syro,Kalman Kovacs,Ricardo V. Lloyd +8 more
TL;DR: This review details the structure and function of endoglin, and investigates the role ofendoglin in angiogenesis and tumor diagnosis, prognosis, and therapy.
Journal ArticleDOI
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
Sylvia L. Asa,Olivera Casar-Borota,Philippe Chanson,Etienne Delgrange,P Earls,Shereen Ezzat,Ashley B. Grossman,H Ikeda,Naoko Inoshita,Niki Karavitaki,Márta Korbonits,Edward R. Laws,M. B. S. Lopes,Nicholas F. Maartens,Ian E. McCutcheon,Ozgur Mete,Hiroshi Nishioka,Gérald Raverot,Federico Roncaroli,Wolfgang Saeger,Luis V. Syro,Alexandre Vasiljevic,Chiara Villa,Anne Wierinckx,Jacqueline Trouillas +24 more
TL;DR: A new terminology, pituitary neuroendocrine tumor (PitNET), is proposed, which is consistent with that used for other neuro endocrine neoplasms and which recognizes the highly variable impact of these tumors on patients.
Journal ArticleDOI
Aggressive pituitary adenomas—diagnosis and emerging treatments
TL;DR: The need to develop new biomarkers to facilitate the early detection of clinically aggressive pituitary adenomas is highlighted and emerging markers that hold promise for their identification are discussed.
Journal Article
Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis.
TL;DR: A summary of what is known about O(6)-Methylguanine-DNA-methyltransferase, including its structure, function in its pathway, polymorphisms, expression in normal and tumoral tissue, relation to alkylating agent therapy, and possible future applications is presented.
Journal ArticleDOI
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
Kalman Kovacs,Bernd W. Scheithauer,Matilde Lombardero,Roger E. McLendon,Luis V. Syro,Humberto Uribe,Leon D. Ortiz,Luis C. Penagos +7 more
TL;DR: This study investigated MGMT immunopositivity in the above noted cases and in an additional three pituitary adenomas studied, and showed lack of MGMT staining in the responsive tumor and high expression in the resistant tumor.